PT  - JOURNAL ARTICLE
AU  - Candace Makeda Moore
AU  - Ruslan Sergienko
AU  - Ronen Arbel
TI  - SARS-CoV-2 alpha variant: is it really more deadly? A population level observational study
AID  - 10.1101/2021.08.17.21262167
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.17.21262167
4099  - http://medrxiv.org/content/early/2021/08/18/2021.08.17.21262167.short
4100  - http://medrxiv.org/content/early/2021/08/18/2021.08.17.21262167.full
AB  - Background In 2021 a new variant of SARS-CoV-2, which came to be called the alpha variant, spread around the world. There were conflicting reports on this COVID-19 variant strain’s potentially increased lethality. In Israel, this strain became predominant in a very short time period.Methods COVID-19 mortality and case fatality rates were examined in Israel in terms of weekly and cumulative numbers.Results COVID-19 case fatality rates in Israel rose quickly at the beginning of the pandemic and peaked in May 2020. The highest crude mortality came later in the second and third waves, but case the case fatality rates did not rise in 2021 with the increasing dominance of the alpha variant.Conclusions Based on the results of examining case-fatality and mortality rates, we concluded that while the alpha variant of the virus raised mortality, in line with the fact that it is more infectious than wild-type, once this strain was caught by patients in Israel, it was not more likely to kill them than the original strainCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe MaxCor lab is the recipient of funds from the Israel Institute for Health Policy Research with grant number 2020/442. The funder had no direct role in the development of the report or analysis and no involvement in the publication process.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was purely observational based on publicly available datasets and published research, and therefore did not require an IRB or oversight body approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this article was made from the original publically available data of the Israel Ministry of Health online, and is cited. In some cases, data has been processed from this original data.